Drug-eluting stents: An early systematic review to inform policy

European Heart Journal

Volumn 25, Issue 11, 2004, Pages 902-919

  Hill, Ruaraidh A ^a   Dündar, Yenal ^a   Bakhai, Ameet ^b   Dickson, Rumona ^a   Walley, Tom ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b BARNET HOSPITAL   (United Kingdom)

Author keywords

Drug eluting stents; Health technology assessment; Interventional cardiology; Policy; Stents; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; DACTINOMYCIN; DEXAMETHASONE; EVEROLIMUS; FIBRINOGEN RECEPTOR; HEPARIN; PACLITAXEL; RAPAMYCIN; TAXANE DERIVATIVE; TICLOPIDINE;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEATH; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; MORTALITY; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VALIDATION PROCESS;

CORONARY RESTENOSIS; DRUG IMPLANTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; RANDOMIZED CONTROLLED TRIALS; STENTS; TREATMENT OUTCOME;

EID: 3042711337     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.03.023     Document Type: Review

References (55)

1. King S. Why have stents replace balloons? Underwhelming evidence. Ann. Intern. Med. 138:2003;842-843
2. Brophy J., Belisle P., Joseph L. Evidence for use of coronary stents: a hierarchical Bayesian meta-analysis. Ann. Intern. Med. 138:2003
3. National Institute for Clinical Excellence. Guidance on coronary artery stents in the treatment of ischaemic heart disease (Technology Appraisal Guidance no. 4), 2000. Available from: http://www.nice.org.uk/Embcat.asp?page= oldsite/appraisals/ihd_guide.htm&d=631
4. Rotter M., Pfiffner D., Maier W., et al. Interventional cardiology in Europe 1991. Eur. Heart J. 24:2003;1164-1170
5. British Cardiovascular Intervention Society (BCIS). BCIS - Audit Section, 2002. Available from: http://www.bcis.org.uk/audit/index.html
6. Meads C., Cummins C., Jolly K., et al. Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. Health Technol. Assessment (Winchester, England). 4:2000;1-153
7. British Cardiac Society, British Cardiovascular Intervention Society (BCIS). Submission document for NICE re-appraisal of coronary stenting 2002/2003; 2002
8. Waksman R., Raizner A.E., Yeung A.C., et al. Use of localised intracoronary [beta] radiation in treatment of in-stent restenosis: The INHIBIT randomised controlled trial. Lancet. 359:2002;551-557
9. Jenkins N.P., Prendergast B.D., Thomas M. Drug eluting coronary stents. BMJ. 325:2002;1315-1316
10. Fattori R., Piva T. Drug-eluting stents in vascular intervention. Lancet. 361:2003;247-249
11. Hill R, Bagust A, Bakhai A, et al. Coronary artery stents: a systematic review and economic evaluation. Health Technol Assessment, in press
12. Cordis. Two-Year SIRIUS Trial Follow-up Shows Sustained Outstanding Performance of CYPHER(TM) Sirolimus-eluting Coronary Stent (Press Release), 2003. Available from: http://www.crtonline.org/body2.cfm?id=205&ArticleID= 252
13. ACC Expert Consensus Panel. ACC expert consensus document on coronary artery stents. JACC 1998;32:1471-1482
14. Manufacturers' and others' submissions to NICE: Drug eluting stents for prevention of restenosis, including review of coronary artery stents for ischaemic heart disease. London: National Institute for Clinical Excellence; 2002
15. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. York: NHS Centre for Reviews and Dissemination University of York; 2001
16. Review Manager (RevMan) [Computer program]. In: Version 4.2 for Windows ed. Oxford, England: The Cochrane Collaboration; 2003
17. Park S.-J., Shim W.H., Ho D.S., et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N. Engl. J. Med. 348:2003;1537-1545
18. Knopf W., O'Neill W., Midei M., et al. The DELIVER clinical trial: 30-day safety data from a multicenter, randomized clinical evaluation of the ACHIEVE drug-eluting coronary stent system. Am. J. Card. 90(suppl. 6A):2002;70H
19. Gershlick A., De Scheerder I., Chevalier B. Long-term follow-up in the ELUTES clinical study. Am. J. Card. 90:2002;1H
20. Heldman A. The PATENCY Pilot Trial: First report/PATENCY PAclitaxel-coated LogicsTENt for the CYtostatic prevention of restenosis. A roll-in feasibility study. Transcatheter Cardiovascular Therapeutics (TCT), 2002. Available from: http://www.tctmd.com/display/expert/pdf/47017/Heldman- PATENCY.pdf
21. Grube E., Silber S., Hauptmann K.E., et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 107:2003;38-42
22. Colombo A. TAXUS II Twelve month clinical follow up of TAXUS II paclitaxel-eluting stent study, 2003. Available from: http://www.tctmd.com/ display/expert/pdf/67869/Colombo-TaxusII.pdf
23. Stone G. TAXUS-IV The pivotal, prospective, randomized trial of the slow-rate polymer-based based paclitaxel-eluting TAXUS stent. Clinical overview and subset analysis. Transcatheter Cardiovascular Therapeutics (TCT), 2003. Available from: http://www.tctmd.com/display/expert/pdf/78433/GWS-TAXUSsymp.pdf
24. Grube E. The SCORE randomized TRIAL QuaDDS-QP2 stent with a polymer sleeve delivery system lessons learned from a pioneering study. TCT 2002, Washington, DC, September 25-28, 2002. Available from: http://www.tctmd.com/ display/expert/pdf/58043/Grube-SCOREDESS2.pdf
25. Schofer J., Schluter M., Gershlick A.H., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). The Lancet. 362:2003;1093-1099
26. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346:2002;1773-1780
27. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349:2003;1315-1323
28. Grube E. Animal and first human results with the biosensors everolimus-eluting stent (FUTURE-I) TCT 2002, Washington, DC, September 25-28, 2002. Available from: http://www.tctmd.com/display/expert/pdf/53477/Grube- Everolimus.pdf
29. Grube E. FUTURE II: Multicenter evaluation of the bioabsorbable polymer-based everolimus-eluting stent. Transcatheter Cardiovascular Therapeutics (TCT), 2003. Available from: http://www.tctmd.com/display/expert/ pdf/80013/FUTURE.pdf
30. Serruys P. Final ACTION results (ActinomycinD) ACTinomycin-eluting stent improves outcomes by reducing neointimal hyperplasia - ACTION TCT 2002, Washington, DC, September 25-28, 2002. Available from: http://www.tctmd.com/ expert-presentations/table-2.html?product_id=3801
31. Knopf W. DELIVER I: final results and afterthoughts. Drug-eluting stent summit @ Transcatheter Cardiovascular Therapeutics (TCT), 2003. Available from: http://www.tctmd.com/display/expert/pdf/79872/knopf-deliverdesstct03.pdf
32. Grube E. TAXUS I two year results - sustained benefit over time: Euro PCR, 2003. Available from: http://www.tctmd.com/display/expert/pdf/71176/Grube- TAXUSI.pdf
33. Boston Scientific Corp. Manufacturer submission to NICE: drug eluting stents for prevention of restenosis, including review of coronary artery stents for ischaemic heart disease. London: National Institute for Clinical Excellence; 2002
34. Colombo A., Drzewiecki J., Banning A., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 108:2003;788-794
35. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350:2004;221-231
36. Wood S. TAXUS IV: dramatic reduction in restenosis [heartwire > news; September 15, 2003]. Available from: http://www.theheart.org/index.cfm?doc_id= 37905&nl_id=tho15sep03
37. Cordis. Manufacturer submission to NICE: Drug eluting stents for prevention of restenosis, including review of coronary artery stents for ischaemic heart disease. London: National Institute for Clinical Excellence; 2002
38. Grube E. Clinical results from FUTURE I and "Future plans, 2003. Available from: http://www.tctmd.com/display/expert/pdf/71172/Grube-FUTURE.pdf
39. Cordis. RAVEL Trial - 2 year clinical follow-up. Cordis submission to NICE; 2003
40. Moses J.W., O'Shaughnessy C., Caputo R., et al. The US multicenter, randomized, double blind study of the sirolimus-eluting stent in coronary lesions: safety outcomes at 9 months. Eur. Heart J. 264:2002
41. Schofer J., Breithardt G., Kuntz R.E., et al. A European multi-centre, randomised, double-blind study of the sirolimus-eluting stent in patients with de novo coronary artery lesions. Eur. Heart J. 4:2002;265
42. Moses JW, Leon MB, Popma JJ, et al. A US multicenter, randomized, double-blind study of the sirolimus-eluting stent in De Novo native coronary lesions. TCT 2002. Slide presentation, 2002. Available from: http://www.tctmd.com/display/expert/pdf/44544/Moses-SIRIUSrevised.pdf
43. Ruygrok P.N., Melkert R., Morel M.A., et al. Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. JACC. 34:1999;1507-1511
44. Clark MA, Bakhai A, Lacey MJ, et al. Clinical and economic outcomes of percutaneous coronary interventions in the elderly: an analysis of medicare claims data. Circulation, In press
45. Gunn J., Morton A.C., Wales C., et al. Drug eluting stents: maximising benefit and minimising cost. Heart. 89:2003;127
46. Cutlip D.E., Chauhan M., Baim D., et al. Clinical restenosis after coronary stenting; perspectives from multicenter trials. JACC. 40:2002;12
47. Kastrati A., Mehilli J., Dirschinger J., et al. Restenosis after coronary placement of various stent types. Am. J. Card. 87:2001;34-39
48. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. The Lancet. 354:1999;1896-1900
49. Clarke M, Oxman A, editors. Cochrane Reviewers' Handbook 4.2.0 [updated March 2003]. Available from: http://www.cochrane.org/resources/handbook/ handbook.pdf
50. Petticrew M. Why certain systematic reviews reach uncertain conclusions. BMJ. 326:2003;756-758
51. Dobrow M., Goel V., Upshur R. Evidence-based health policy: context and utilisation. Social Sci. Med. 58:2004;207-217
52. Weinstein M. Industry update. Drug-Eluting Stents. Physician Survey Suggests Rapid US Adoption. New York: J.P. Morgan Securities Inc. (Equity Research); 2002 15/11/2003
53. National Institute for Clinical Excellence. Appraisal consultation document: drug eluting stents for prevention of restenosis, including review of coronary artery stents for ischaemic heart disease, 2003. Available from: http://www.nice.org.uk/article.asp?a=76197
54. Knopf W, O'Neill W, Fitzgerald P. A premier presentation of DELIVER trial results at CRT 2003. CRT 2003 January 26-29, 2003, Washington. Available from: http://www.crtonline.org/body2.cfm?id=205&ArticleID=79
55. O'Neill WW. The DELIVER trial: a randomized comparison of paclitaxel-coated versus metallic stents for treatment of coronary lesions. American College of Cardiology (ACC) 2003. Available from: http://www.tctmd.com/ display/expert/pdf/68477/DELIVER-acc03.pdf